Literature DB >> 29437145

Report on the NCI Microbial-Based Cancer Therapy Conference.

Colleen S Curran1, Avraham Rasooly2, Min He3, Ben Prickril2, Magdelena Thurin4, Elad Sharon5.   

Abstract

The National Cancer Institute Inaugural Microbial-Based Cancer Therapy Conference was held in Bethesda, Maryland, on July 11-12, 2017. This interdisciplinary forum included industry leaders, academic investigators, and regulatory officers involved in the development of microbial-based therapies for the treatment of cancer. The aim of the meeting was to discuss the potential of virus- and bacteria-based therapies to halt tumorigenesis and induce immune responses in cancers where conventional therapy is inadequate. This summary highlights topics and viewpoints raised by the presenters and discussants and should not be viewed as the conclusions or recommendations of the workshop as a whole. Cancer Immunol Res; 6(2); 122-6. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 29437145     DOI: 10.1158/2326-6066.CIR-17-0748

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  4 in total

1.  Bugs as Cancer Drugs: Challenges and Opportunities.

Authors:  Phillip J Daschner; Avraham Rasooly; Jeffrey D White
Journal:  Mol Cell Biol       Date:  2019-07-16       Impact factor: 4.272

2.  Bugs as Drugs, potential self-regenerated innovative cancer therapeutics approach for global health.

Authors:  Luis Alejandro Salicrup; Miguel Ossandon; Ben Prickril; Avraham Rasooly
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

Review 3.  Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment.

Authors:  Shruti S Sawant; Suyash M Patil; Vivek Gupta; Nitesh K Kunda
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

4.  Interventional Optical Imaging-Monitored Synergistic Effect of Radio-Frequency Hyperthermia and Oncolytic Immunotherapy.

Authors:  Hui Zheng; Feng Zhang; Wayne Monsky; Hongxiu Ji; Weizhu Yang; Xiaoming Yang
Journal:  Front Oncol       Date:  2022-01-24       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.